Atossa Genetics (NASDAQ:ATOS) Shares Pass Below 200-Day Moving Average – Here’s Why

Atossa Genetics Inc. (NASDAQ:ATOS)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $7.49 and traded as low as $4.86. Atossa Genetics shares last traded at $4.95, with a volume of 30,295 shares traded.

Wall Street Analyst Weigh In

ATOS has been the topic of a number of recent research reports. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. HC Wainwright boosted their price objective on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Ascendiant Capital Markets reduced their target price on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $36.33.

Atossa Genetics Stock Down 0.2%

The company has a fifty day moving average price of $5.28 and a 200 day moving average price of $7.49. The stock has a market cap of $42.62 million, a PE ratio of -1.54 and a beta of 1.25.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). As a group, research analysts predict that Atossa Genetics Inc. will post -4.41 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Atossa Genetics by 51.3% during the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after buying an additional 37,809 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Atossa Genetics during the second quarter valued at about $381,000. Ameriprise Financial Inc. purchased a new stake in shares of Atossa Genetics during the second quarter worth about $2,468,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the second quarter worth about $26,000. 12.74% of the stock is currently owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.